Direct answer: In September 2026, FDA issued a draft pre-market declaration on robotic para-surgery equipment (RASD) to discuss non-clinical tests, clinical information and labelling recommendations. This document, which is clearly marked as Draft - Not for Application, is for comment only and should not be considered as a final guide or mandatory obligation at this time. The deadline for comments listed on the FDA page is 24 November 2026.The nature of the document, the current status and the enterprise recommendations are set out below; Specific products should be judged in the official language.
What is this file, at what stage?
The regulatory document and its status referred to in this paper is based on the original FDA page listing. The draft may be revised, the duration of the comments and the current status should be based on the FDA and Federal Reserve pages.
A distinction should be made between binding regulations/final rules and FDA guides, drafts, discussion papers or enforcement policies. The latter have different legal effects; Specific sources of restraint are governed by the documents and by the legislation cited.
Which enterprises and products need attention?
Manufacturers of robotic assisted surgical equipment and teams preparing for pre-market declarations on research and development, clinical, quality and regulation.
It is recommended that this be confirmed on a product-business role-US market-based basis; Where product classifications or responsible subjects cannot be judged by name alone, the labels are subject to individual checks.
Where is the change from what was previously requested?
The substance of the document and the background to the previous rules are set out below. Only changes specified in official documents are considered to be changes; The recommendatory content is not to be added to the mandatory obligation.
Direct answer:In September 2026, FDA issued a draft pre-market declaration on robotic para-surgery equipment (RASD) to discuss non-clinical tests, clinical information and labelling recommendations. This document, which is clearly marked as Draft - Not for Application, is for comment only and should not be considered as a final guide or mandatory obligation at this time. The deadline for comments listed on the FDA page is 24 November 2026.
- Support non-clinical tests and performance information declared prior to listing.
- Clinical data considerations applicable to specific equipment.
- Tag content and information relevant to the use and operator of the device.
- Describes system components, surgical devices, software control methods and intended clinical uses.
- Check product classifications, application of pre-market paths and draft exclusions.
- Establish a catalogue of information on racks/non-clinical tests, software validation, risk management and clinical evidence.
- The draft recommendation is marked as a planned input to be confirmed in the final document and is not considered to be directly valid as a criterion.
- Focus on the publication of the follow-up final guide to docket and FDA.
Key dates and transitional arrangements
The following dates are derived from the factual summary of the documents retained here. A distinction should be made between the date of issuance, the date of closure of comments and the date of entry into force/application of the respective documents. There is no presumption in respect of matters that are not clearly stated in the original text.
- September 2026: Date of issuance of the document (as expressed in the original language of the adjacent official).
- 24 November 2026: Comments/due date of submission (as expressed in the original language of the neighbouring Government).
The date of publication/update of the website’s articles does not correspond to the date of implementation of the statute; If the dates of the official pages differ, reference is made to the official document and the current FDA page.
How can Chinese companies prepare?
- (b) To organize non-clinical performance, human factors, clinical evidence, software/network security and labelling according to intended use and operating environment; Article-by-article recording of differences against draft.
- Identify those responsible, sources and internal review nodes, and maintain official page versions and verification dates.
- If the official document is revised, withdrawn or the final version issued, the applicable conclusions are reassessed and the records updated.
For this purpose, the recommendation does not substitute for the obligation set out in the body of the statute.
Exceptions, pending confirmations and common misreading
- The draft may be revised, the duration of the comments and the current status should be based on the FDA and Federal Reserve pages.
- When exemptions, transition periods, border products or different business actors are encountered, the original text should be consulted on the basis of specific facts; Uncertainties should be clearly identified for confirmation.
- Registration, listing, submission or obtaining of a reply should not be mistakenly referred to as FDA approval or authentication.
Official information and reconciliation records
- FDA:Robotically-Assisted Surgical Devices – Premarket Submissions(Draft Guidance)
- FDA: Draft text as a whole
- FDA:Computer-Assisted Surgical Systems
(b) The station’s author: Mr. Toshito. Reviewer: Mr. Toto. Date of the structural review of the article: 2026-11-02; The statutory status and specific obligations are based on the official language listed.
Next
Identification of scope of application by product and corporate role, viewing Regulatory UpdatesAnd the corresponding FDA Compliance Service Scope; If you need a case judgement, you can do it. Contact PageSubmission of product information.